1. The role of pre-operative axillary ultrasound in assessment of axillary tumor burden in breast cancer patients: a systematic review and meta-analysis

   • Vivian Man
   • Wing-Pan Luk
   • Ava Kwong

   Review 22 September 2022 Pages: 245 - 254

   

2. TP53-positive clones are responsible for drug-tolerant persister and recurrence of HER2-positive breast cancer

   • Hideki Watanabe
   • Hiroshi Nakagomi
   • Masao Omata

   Preclinical study 10 September 2022 Pages: 255 - 266

   

3. Improved false-negative rates using a novel patient selection flowchart in initially biopsy-proven node-positive breast cancer undergoing blue-dye alone guided sentinel lymph node biopsy after neoadjuvant chemotherapy

   • Minyan Chen
   • Shengmei Li
   • Fangmeng Fu

   Preclinical study 13 September 2022 Pages: 267 - 277

   

4. Molecular characterization of ESR1 variants in breast cancer

   • Arielle L. Heeke
   • Andrew Elliott
   • Antoinette R. Tan

   Preclinical study 20 September 2022 Pages: 279 - 289

   

5. Absolute lymphocyte count decreases with disease progression and is a potential prognostic marker for metastatic breast cancer

   • Hikari Jimbo
   • Yoshiya Horimoto
   • Junichiro Watanabe

   Preclinical study 26 September 2022 Pages: 291 - 298

   

6. A comparative analysis of recurrence risk predictions in ER+/HER2− early breast cancer using NHS Nottingham Prognostic Index, PREDICT, and CanAssist Breast

   • Aparna Gunda
   • Mallikarjuna S. Eshwaraiah
   • Manjiri M. Bakre

   Clinical trial Open access 10 September 2022 Pages: 299 - 310

7. Dual HER2 blockade with pertuzumab (P) and trastuzumab (T) in patients with HER2-positive metastatic breast cancer (mBC) relapsing after adjuvant treatment with T: results from a German non-interventional study (NIS) HELENA (NCT01777958)

   • Marc Thill
   • Pauline Wimberger
   • Andreas Schneeweiss

   Clinical trial Open access 12 September 2022 Pages: 311 - 321

   

8. Association of sarcopenia with endocrine therapy toxicity in patients with early breast cancer

   • Gabriel Francisco Pereira Aleixo
   • Stephanie A. Valente
   • Halle C. F. Moore

   Clinical trial 17 September 2022 Pages: 323 - 328

9. Impact of body mass index on survival in women receiving chemotherapy for early breast cancer

   • Rossanna C. Pezo
   • Kelvin K. W. Chan
   • Maureen Trudeau

   Clinical trial 17 September 2022 Pages: 329 - 339

   

10. Clinical significance of the neutrophil-to-lymphocyte ratio in oligometastatic breast cancer

    • Yuka Inoue
    • Makoto Fujishima
    • Shinji Ohno

    Clinical trial Open access 24 September 2022 Pages: 341 - 348

    

11. Positive association between body height and breast cancer prevalence: a retrospective study with 135,741 women in Germany

    • Niklas Gremke
    • Sebastian Griewing
    • Karel Kostev

    Epidemiology Open access 10 September 2022 Pages: 349 - 354

    

12. Cancer risks associated with heterozygous ATM loss of function and missense pathogenic variants based on multigene panel analysis

    • Yael Laitman
    • Sarah M. Nielsen
    • Eitan Friedman

    Epidemiology 12 September 2022 Pages: 355 - 361

    

13. Early postoperative psychological distress as a mediator of subsequent persistent postsurgical pain outcomes among younger breast cancer patients

    • Jenna M. Wilson
    • Carin A. Colebaugh
    • Kristin L. Schreiber

    Epidemiology 14 September 2022 Pages: 363 - 370

    

14. Ductal carcinoma in situ of the male breast: clinical radiological features and management in a cancer referral center

    • Luca Nicosia
    • Germana Lissidini
    • Paolo Veronesi

    Epidemiology Open access 17 September 2022 Pages: 371 - 377

    

15. Reproductive history differs by molecular subtypes of breast cancer among women aged ≤ 50 years in Scotland diagnosed 2009–2016: a cross-sectional study

    • Anushri Chitkara
    • Ines Mesa-Eguiagaray
    • Jonine D. Figueroa

    Epidemiology Open access 18 September 2022 Pages: 379 - 387

    

16. Breast cancer polygenic risk scores are associated with short-term risk of poor prognosis breast cancer

    • Anne Marie McCarthy
    • Alisa K. Manning
    • Katrina Armstrong

    Epidemiology 22 September 2022 Pages: 389 - 398

    

17. Are there differences in outcomes by race among women with metastatic triple-negative breast cancer?

    • Bridget A. Oppong
    • Angel A. Rolle
    • Electra D. Paskett

    Epidemiology 24 September 2022 Pages: 399 - 408

    

18. Long-term survival of screen-detected synchronous and metachronous bilateral non-palpable breast cancer among Chinese women: a hospital-based study (2003–2017)

    • Bo Pan
    • Ying Xu
    • Qiang Sun

    Epidemiology Open access 27 September 2022 Pages: 409 - 422

    

19. Blood plasma derived extracellular vesicles (BEVs): particle purification liquid chromatography (PPLC) and proteomic analysis reveals BEVs as a potential minimally invasive tool for predicting response to breast cancer treatment

    • Folnetti A. Alvarez
    • Hussein Kaddour
    • Chioma M. Okeoma

    Brief Communication 17 September 2022 Pages: 423 - 437

    

20. Multigene panel testing might explain the increased risk of secondary malignancies after radiotherapy in Japanese breast cancer patients

    • Kadri Altundag

    Letter to the Editor 10 September 2022 Pages: 439 - 439